QJ-19-0002

Main objectives: 1. Evaluate the tolerance and safety of single and multiple doses in healthy subjects, determine the maximum tolerated dose, and investigate the adverse reaction characteristics of the drug; 2. Evaluate the pharmacokinetic (PK) characteristics of single and multiple doses in healthy subjects, investigate the linear characteristics and accumulation of multiple doses; 3. Evaluate the metabolism and biotransformation characteristics of the drug in healthy subjects; 4. Evaluate the cardiotoxicity of the drug by C-QTc analysis; 5. Evaluate whether there are gender differences in the pharmacokinetics (PK) and pharmacodynamics (PD) of the drug. Secondary objectives: Evaluate the pharmacodynamic (PD) characteristics of healthy subjects after single and multiple doses.